Status:
UNKNOWN
uPAR-PET/MRI in Patients With Prostate Cancer for Evaluation of Tumor Aggressiveness
Lead Sponsor:
Rigshospitalet, Denmark
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE2
Brief Summary
Prospective study to evaluate the value of uPAR-targeted PET/MR scan using the tracer 68Ga-NOTA-AE105 in patients with newly diagnosed prostate cancer
Detailed Description
Prostate cancer is one of the most frequent types of cancer in men. The characteristics of the disease varies significantly among patients where some have an indolent type of cancer, from which they w...
Eligibility Criteria
Inclusion
- Histologically verified prostate cancer
- Capable of understanding written information and giving informed consent
- Planned to enter active surveillance strategy or undergo therapy with curative intent (surgery or radiotherapy)
Exclusion
- Obesity (Body weight over 140 kg)
- Known allergy to 68-Ga-NOTA-AE105
- Metallic components in the body that contradicts MRI scan
- Severe claustrophobia making the person unable to complete an MRI scan
Key Trial Info
Start Date :
November 21 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2022
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT03307460
Start Date
November 21 2017
End Date
April 1 2022
Last Update
November 23 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rigshospitalet
Copenhagen, Denmark, 2100